Reactive oxygen species in redox cancer therapy

Cancer Letters

Volumn 367, Issue 1, 2015, Pages 18-25

  Tong, Lingying ^a   Chuang, Chia Chen ^b   Wu, Shiyong ^a   Zuo, Li ^b,c  

^a OHIO UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Antioxidant; Cancer therapy; Oxidative stress; Redox; Tumor

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; ELESCLOMOL; EPIGALLOCATECHIN GALLATE; HYDROGEN PEROXIDE; NITRIC OXIDE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SELENIUM; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; ANTIOXIDANT;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; DIET SUPPLEMENTATION; DRUG CYTOTOXICITY; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY CHAIN; RISK BENEFIT ANALYSIS; SCAVENGING SYSTEM; SHORT SURVEY; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84939261397     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.008     Document Type: Review

References (95)

1. Magder S. Reactive oxygen species: toxic molecules or spark of life?. Crit. Care 2006, 10(1):208.
2. Schieber M., Chandel N.S. ROS function in redox signaling and oxidative stress. Curr. Biol 2014, 24(10):R453-R462.
3. Siti H.N., Kamisah Y., Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul. Pharmacol 2015, Apr 11. pii: S1537-1891(15)00042-7; [Epub ahead of print]. 10.1016/j.vph.2015.03.005.
4. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes 2015, 6(3):456-480.
5. Karaaslan C., Suzen S. Antioxidant properties of melatonin and its potential action in diseases. Curr. Top. Med. Chem 2015, 15(9):894-903.
6. Halliwell B. Antioxidants in human health and disease. Annu. Rev. Nutr 1996, 16:33-50.
7. Mendelsohn A.R., Larrick J.W. Paradoxical effects of antioxidants on cancer. Rejuvenation Res 2014, 17(3):306-311.
8. Patterson R.E., White E., Kristal A.R., Neuhouser M.L., Potter J.D. Vitamin supplements and cancer risk: the epidemiologic evidence. Cancer Causes Control 1997, 8(5):786-802.
9. Conklin K.A. Cancer chemotherapy and antioxidants. J. Nutr 2004, 134(11):3201S-3204S.
10. Lawenda B.D., Kelly K.M., Ladas E.J., Sagar S.M., Vickers A., Blumberg J.B. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?. J. Natl. Cancer Inst 2008, 100(11):773-783.
11. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417(1):1-13.
12. Thomas C., Mackey M.M., Diaz A.A., Cox D.P. Hydroxyl radical is produced via the Fenton reaction in submitochondrial particles under oxidative stress: implications for diseases associated with iron accumulation. Redox Rep 2009, 14(3):102-108.
13. Kumar S., Rhim W.K., Lim D.K., Nam J.M. Glutathione dimerization-based plasmonic nanoswitch for biodetection of reactive oxygen and nitrogen species. ACS Nano 2013, 7(3):2221-2230.
14. Marlatt M., Lee H.G., Perry G., Smith M.A., Zhu X. Sources and mechanisms of cytoplasmic oxidative damage in Alzheimer's disease. Acta Neurobiol. Exp. (Wars) 2004, 64(1):81-87.
15. Munzel T., Daiber A., Ullrich V., Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler. Thromb. Vasc. Biol 2005, 25(8):1551-1557.
16. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev 2007, 87(1):245-313.
17. Paravicini T.M., Touyz R.M. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008, 31(Suppl. 2):S170-S180.
18. Yao J., Liu Y., Wang X., Shen Y., Yuan S., Wan Y., et al. UVB radiation induces human lens epithelial cell migration via NADPH oxidase-mediated generation of reactive oxygen species and up-regulation of matrix metalloproteinases. Int. J. Mol. Med 2009, 24(2):153-159.
19. Liu W., Wu S. Differential roles of nitric oxide synthases in regulation of ultraviolet B light-induced apoptosis. Nitric Oxide 2010, 23(3):199-205.
20. Wu S., Wang L., Jacoby A.M., Jasinski K., Kubant R., Malinski T. Ultraviolet B light-induced nitric oxide/peroxynitrite imbalance in keratinocytes - implications for apoptosis and necrosis. Photochem. Photobiol 2010, 86(2):389-396.
21. Riley P.A. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int. J. Radiat. Biol 1994, 65(1):27-33.
22. Yamamori T., Yasui H., Yamazumi M., Wada Y., Nakamura Y., Nakamura H., et al. Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. Free Radic. Biol. Med 2012, 53(2):260-270.
23. Guzy R.D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K.D., et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005, 1(6):401-408.
24. Trujillo M., Ferrer-Sueta G., Radi R. Peroxynitrite detoxification and its biologic implications. Antioxid. Redox Signal 2008, 10(9):1607-1620.
25. Cabello C.M., Bair W.B., Wondrak G.T. Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr. Opin. Investig. Drugs 2007, 8(12):1022-1037.
26. Itoh K., Ye P., Matsumiya T., Tanji K., Ozaki T. Emerging functional cross-talk between the Keap1-Nrf2 system and mitochondria. J Clin Biochem Nutr 2015, 56(2):91-97.
27. Gorrini C., Harris I.S., Mak T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov 2013, 12(12):931-947.
28. Chen X., Qian Y., Wu S. The Warburg effect: evolving interpretations of an established concept. Free Radic. Biol. Med 2015, 79C:253-263.
29. Finkel T. Signal transduction by mitochondrial oxidants. J. Biol. Chem 2012, 287(7):4434-4440.
30. Granger D.L., Lehninger A.L. Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells. J. Cell Biol 1982, 95(2 Pt 1):527-535.
31. Genova M.L., Bianchi C., Lenaz G. Supercomplex organization of the mitochondrial respiratory chain and the role of the coenzyme Q pool: pathophysiological implications. Biofactors 2005, 25(1-4):5-20.
32. Waris G., Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinog 2006, 5:14.
33. Pelengaris S., Khan M. The many faces of c-MYC. Arch. Biochem. Biophys 2003, 416(2):129-136.
34. Liou G.Y., Storz P. Reactive oxygen species in cancer. Free Radic. Res 2010, 44(5):479-496.
35. Sun C., Zhang H., Ma X.F., Zhou X., Gan L., Liu Y.Y., et al. Isoliquiritigenin enhances radiosensitivity of HepG2 cells via disturbance of redox status. Cell Biochem. Biophys 2013, 65(3):433-444.
36. Büchner F.L., Bueno-de-Mesquita H.B., Linseisen J., Boshuizen H.C., Kiemeney L.A., Ros M.M., et al. Fruits and vegetables consumption and the risk of histological subtypes of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2010, 21(3):357-371.
37. Glasauer A., Chandel N.S. Targeting antioxidants for cancer therapy. Biochem. Pharmacol 2014, 92(1):90-101.
38. Ostrakhovitch E.A. Redox environment and its meaning for breast cancer cells fate. Curr. Cancer Drug Targets 2011, 11(4):479-495.
39. Kirshner J.R., He S., Balasubramanyam V., Kepros J., Yang C.Y., Zhang M., et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer Ther 2008, 7(8):2319-2327.
40. Ramanathan B., Jan K.Y., Chen C.H., Hour T.C., Yu H.J., Pu Y.S. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 2005, 65(18):8455-8460.
41. Lin C., Yu Y., Zhao H.G., Yang A., Yan H., Cui Y. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother. Oncol 2012, 104(3):395-400.
42. Yi L., Zongyuan Y., Cheng G., Lingyun Z., Guilian Y., Wei G. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci 2014, 105(5):520-527.
43. Zhang X., Yeung E.D., Wang J., Panzhinskiy E.E., Tong C., Li W., et al. Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells. Clin. Exp. Pharmacol. Physiol 2010, 37(8):841-847.
44. Scarlatti F., Sala G., Ricci C., Maioli C., Milani F., Minella M., et al. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 2007, 253(1):124-130.
45. Miki H., Uehara N., Kimura A., Sasaki T., Yuri T., Yoshizawa K., et al. Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. Int. J. Oncol 2012, 40(4):1020-1028.
46. Hotnog D., Mihaila M., Lancu I.V., Matei G.G., Hotnog C., Anton G., et al. Resveratrol modulates apoptosis in 5-fluorouracyl treated colon cancer cell lines. Roum. Arch. Microbiol. Immunol 2013, 72(4):255-264.
47. Kma L. Synergistic effect of resveratrol and radiotherapy in control of cancers. Asian Pac. J. Cancer Prev 2013, 14(11):6197-6208.
48. Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011, 306(14):1549-1556.
49. Dunn B.K., Richmond E.S., Minasian L.M., Ryan A.M., Ford L.G. A nutrient approach to prostate cancer prevention: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr. Cancer 2010, 62(7):896-918.
50. Kristal A.R., Darke A.K., Morris J.S., Tangen C.M., Goodman P.J., Thompson I.M., et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J. Natl. Cancer Inst 2014, 106(3):djt456.
51. Karp D.D., Lee S.J., Keller S.M., Wright G.S., Aisner S., Belinsky S.A., et al. Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J. Clin. Oncol 2013, 31(33):4179-4187.
52. Al Dhaheri Y., Attoub S., Ramadan G., Arafat K., Bajbouj K., Karuvantevida N., et al. Carnosol induces ROS-mediated beclin1-independent autophagy and apoptosis in triple negative breast cancer. PLoS ONE 2014, 9(10):e109630.
53. Hao W., Zhang X., Zhao W., Chen X. Psoralidin induces autophagy through ROS generation which inhibits the proliferation of human lung cancer A549 cells. Peer J. 2014, 2:e555.
54. Ghosh P., Singha Roy S., Basu A., Bhattacharjee A., Bhattacharya S. Sensitization of cisplatin therapy by a naphthalimide based organoselenium compound through modulation of antioxidant enzymes and p53 mediated apoptosis. Free Radic. Res 2015, 49(4):453-471.
55. Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria in cancer cells: what is so special about them?. Trends Cell Biol 2008, 18(4):165-173.
56. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov 2010, 9(6):447-464.
57. Song I.S., Jeong J.Y., Jeong S.H., Kim H.K., Ko K.S., Rhee B.D., et al. Mitochondria as therapeutic targets for cancer stem cells. World J Stem Cells 2015, 7(2):418-427.
58. Choi E.J., Chee K.M., Lee B.H. Anti- and prooxidant effects of chronic quercetin administration in rats. Eur. J. Pharmacol 2003, 482(1-3):281-285.
59. Korge P., Calmettes G., Weiss J.N. Increased reactive oxygen species production during reductive stress: the roles of mitochondrial glutathione and thioredoxin reductases. Biochim. Biophys. Acta 2015, 1847(6-7):514-525.
60. Borek C. Antioxidants and radiation therapy. J. Nutr 2004, 134(11):3207S-3209S.
61. Filippova M., Filippov V., Williams V.M., Zhang K., Kokoza A., Bashkirova S., et al. Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agents. Biomed Res Int 2014, 2014:574659.
62. Jayakumar S., Kunwar A., Sandur S.K., Pandey B.N., Chaubey R.C. Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. Biochim. Biophys. Acta 2014, 1840(1):485-494.
63. Xiang L., Xie G., Liu C., Zhou J., Chen J., Yu S., et al. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim. Biophys. Acta 2013, 1833(12):2996-3005.
64. Brown C.O., Salem K., Wagner B.A., Bera S., Singh N., Tiwari A., et al. Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase. Biochem. J. 2012, 444(3):515-527.
65. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med 2005, 142(1):37-46.
66. Chang Y.J., Myung S.K., Chung S.T., Kim Y., Lee E.H., Jeon Y.J., et al. Effects of vitamin treatment or supplements with purported antioxidant properties on skin cancer prevention: a meta-analysis of randomized controlled trials. Dermatology 2011, 223(1):36-44.
67. Cabanillas F. Vitamin C and cancer: what can we conclude - 1,609 patients and 33 years later?. P. R. Health Sci. J. 2010, 29(3):215-217.
68. Albanes D., Heinonen O.P., Taylor P.R., Virtamo J., Edwards B.K., Rautalahti M., et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J. Natl. Cancer Inst 1996, 88(21):1560-1570.
69. Wong J.L., Creton R., Wessel G.M. The oxidative burst at fertilization is dependent upon activation of the dual oxidase Udx1. Dev. Cell 2004, 7(6):801-814.
70. Finkel T. Signal transduction by reactive oxygen species. J. Cell Biol 2011, 194(1):7-15.
71. Griveau J.F., Renard P., Le Lannou D. An in vitro promoting role for hydrogen peroxide in human sperm capacitation. Int. J. Androl 1994, 17(6):300-307.
72. de Lamirande E., O'Flaherty C. Sperm activation: role of reactive oxygen species and kinases. Biochim. Biophys. Acta 2008, 1784(1):106-115.
73. Cheng J.C., Klausen C., Leung P.C. Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett 2013, 329(2):197-206.
74. Panieri E., Gogvadze V., Norberg E., Venkatesh R., Orrenius S., Zhivotovsky B. Reactive oxygen species generated in different compartments induce cell death, survival, or senescence. Free Radic. Biol. Med 2013, 57:176-187.
75. West A.P., Brodsky I.E., Rahner C., Woo D.K., Erdjument-Bromage H., Tempst P., et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 2011, 472(7344):476-480.
76. Poillet-Perez L., Despouy G., Delage-Mourroux R., Boyer-Guittaut M. Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol 2015, 4:184-192.
77. Li L., Ishdorj G., Gibson S.B. Reactive oxygen species regulation of autophagy in cancer: implications for cancer treatment. Free Radic. Biol. Med 2012, 53(7):1399-1410.
78. Azad M.B., Chen Y., Gibson S.B. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid. Redox Signal 2009, 11(4):777-790.
79. Galati G., Sabzevari O., Wilson J.X., O'Brien P.J. Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 2002, 177(1):91-104.
80. Wu S. New life for an "old" drink. Cell Cycle 2009, 8(13):1979-1980.
81. Galati G., Lin A., Sultan A.M., O'Brien P.J. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic. Biol. Med 2006, 40(4):570-580.
82. Bleys J., Navas-Acien A., Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch. Intern. Med 2008, 168(4):404-410.
83. Clark L.C., Combs G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276(24):1957-1963.
84. Duffield-Lillico A.J., Dalkin B.L., Reid M.E., Turnbull B.W., Slate E.H., Jacobs E.T., et al. Nutritional Prevention of Cancer Study G: selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003, 91(7):608-612.
85. Duntas L.H., Benvenga S. Selenium: an element for life. Endocrine 2015, 48(3):756-775.
86. Lipinski B. Rationale for the treatment of cancer with sodium selenite. Med. Hypotheses 2005, 64(4):806-810.
87. Tobe T., Ueda K., Ando M., Okamoto Y., Kojima N. Thiol-mediated multiple mechanisms centered on selenodiglutathione determine selenium cytotoxicity against MCF-7 cancer cells. J. Biol. Inorg. Chem 2015, 20(4):687-694.
88. Zhang H., Limphong P., Pieper J., Liu Q., Rodesch C.K., Christians E., et al. Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J. 2012, 26(4):1442-1451.
89. Sayin V.I., Ibrahim M.X., Larsson E., Nilsson J.A., Lindahl P., Bergo M.O. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 2014, 6(221):221ra15.
90. Savas E., Aksoy N., Pehlivan Y., Sayiner Z.A., Ozturk Z.A., Tabur S., et al. Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis. Wien. Klin. Wochenschr 2014, 126(11-12):341-346.
91. Rose A.H., Bertino P., Hoffmann F.W., Gaudino G., Carbone M., Hoffmann P.R. Increasing dietary selenium elevates reducing capacity and ERK activation associated with accelerated progression of select mesothelioma tumors. Am. J. Pathol 2014, 184(4):1041-1049.
92. Shelton P., Jaiswal A.K. The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?. FASEB J. 2013, 27(2):414-423.
93. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29(6):1235-1243.
94. Berhane H., Epperly M.W., Cao S., Goff J.P., Franicola D., Wang H., et al. Radioresistance of bone marrow stromal and hematopoietic progenitor cell lines derived from Nrf2-/- homozygous deletion recombinant-negative mice. In Vivo 2013, 27(5):571-582.
95. Fuchs-Tarlovsky V. Role of antioxidants in cancer therapy. Nutrition 2013, 29(1):15-21.